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S. STROBEL  The Hospital for Sick Children, London Report of the  Scientific Committee 
for  Food on  infant formulae 
claimed  to  be 
"hypoallergenic"  or  "hypoantigenic" 
(Opinion  expressed  on  9  December  1991) 
Terms  of  Reference 
To advise on the minimum requirements of infant formulae based on protein hydrolysates 
presented as "hypoallergenic" or "hypoantigenic" products. 
Introduction 
1 .  Over the last years, the Committee adopted two reports on the minimum requirements of 
infant formulae  and follow-up  formulae  based on cows' milk proteins  1  and soya 
proteins 2. These reports have been supplemented by two addenda listing the nutritional 
substances which may be used in the preparation of these products 3.4. 
2 .  Products based on high degree protein hydrolysates from different sources (primarily 
casein and/or lactoserum proteins) have been available for more than 40 years. They 
were and still are used mainly to treat various digestive disorders resulting from external 
pancreatic insufficiency, short bowel syndrome, enteropathies of various etiologies and 
proven allergy to cows' milk proteins. These products, which obviously belong to the 
category of "dietetic food for special medical use", are generally subjected to other 
modifications, especially in regard to their carbohydrate and fat content, in order to 
increase their efficacy in  the treatment of gastrointestinal disorders and to  prevent 
malnutrition 5-10. 
3 .  Besides these classical semi-elemental diets for therapeutic use, new products based on 
hydrolysed proteins, presented as "hypoallergenic" or "hypoantigenic" formulae have 
been on the market since 1987  11-13. According to manufacturers, at present, they are 
sold in  at least five EC member states, the USA and Canada 14.  They correspond to a 
more or less high degree hydrolysate. Due to the technological procedures used, these 
formulae have an at least 100 fold reduction of the major antigenic content compared with 
standard adapted milk formulae. This report deals with the above mentioned products 
and the conditions warranting the claims "hypoallergenic" or "hypoantigenic". 2  Reports of the Scientific Committee for Food:  28th series 
Definitions 
4.  The definitions and conversion factors used in the reports cited above 1.2 and in the first 
Report of the Scientific Committee for Food on the essential requirements for weaning 
foods 15 also apply in this report. 
5 .  On the other hand, in order to  avoid confusions as regards semantics, the following 
definitions have been adopted for this report: 
Antigen: 
Allergen: 
Allergy: 
Atopy: 
A substance that can induce an immune response. 
An antigen capable of inducing an allergic response. 
Pathological clinical reaction after exposure to an allergen in persons 
already sensitized by a previous contact, irrespective of the underlying 
immunological mechanism. 
Constitutional anomaly consisting of a hyperreactivity to environmental 
substances, connected with an altered IgE regulation. 
Anaphylaxis:  Immediate hypersensitivity reactions (Type I of Gell and Coombs 
Tolerance: 
Food 
intolerance: 
classification) involving the interaction of  an antigen with IgE. 
Desirable clinical (and immunological) hypo-responsiveness after a 
food, bacterial or viral antigen are repeatedly administered via the oral 
route. 
Undesirable reaction  to  a  certain food  or a  specific ingredient of 
variable etiology (enzymatic deficiency, toxic, infectious, etc.) but 
where there is no known relationship with immunity. 
Food  allergy:  Clinical hypersensitivity reaction involving all arms of the immune 
system (humoral, IgE, IgG, IgA, etc.) and/or cellular mechanisms. 
At risk infant: Infants of one or two allergic parents and/or whose IgE level in cord 
blood exceeds 0.7 U/ml . 
Documents  consulted 
6.  In drafting this report, the Committee considered the data in the literature, the opinions 
adopted by  the  Committee on  Nutrition  of the  European  Society for  Paediatric 
Gastroenterology and Nutrition  (ESPGAN)  16, the report of the Sub-Committee on 
Nutrition and Allergic Disease of the American Academy of Pediatrics  17  and the 
information provided by  the  Association of Dietetic Foods Industries of the  EEC 
(IDACE), especially concerning the characteristics of products now on the market, the 
results  of  current  experiences  and  conditions  which  allow  the  claim  of 
"hypoallergenicity".  · 
General  Considerations 
7 .  All dietary proteins, and especially cows' milk proteins, can cause various clinical 
disorders affecting virtually all organ systems. These can develop in the digestive tract in 
acute or chronic forms, in  the respiratory system (asthma, spasmodic rhinitis), in the Infant formulae claimed to  be  "hypoallergenic" or "hypoantigenic": 9-12-1991  3 
skin (urticaria, atopic eczema, contact dermatitis) and include anaphylactic shocks, all of 
which are recognized allergic symptoms 18,19. 
8.  Allergy is  one of the  most significant morbidity factors  in  industrialized countries, 
affecting 20 to 35 %of the population 20,21. The prevalence of food allergy itself varies 
according to statistics between 0.3 to almost 50 %. However, these extreme values are 
not realistic 22 and it is more reasonable to consider the prevalence of milk allergy as 
being around 2 to 7 %  23-25. 
9 .  The risk of developing atopic disorders is approximately two times greater for infants 
where one parent or one brother or sister suffers from  an  allergy, compared with the 
normal population, and this  risk is  three times higher if both parents have allergic 
diseases 20. Moreover, the risk of developing an atopic disease is much higher in infants 
in which the total IgE level in the cord blood is above 0.7 kU/L, compared with children 
in which the IgE level is below this value (52 %versus 13  %). The IgE level in cord 
blood is  most frequently elevated in newborns with a family history of allergy 20,26. 
Moreover, the risk of developing atopic disorders is around 3 in 4 (75%) for infants with 
an allergic family history and an elevated cord blood IgE level, while it is only 1 in 30 for 
infants without increased IgE level and no family history of allergy 27. It is important to 
consider that around 3 % of infants are born to two atopic parents and that almost 10 % 
of newborns have an  elevated IgE level at birth 28.  And finally, despite contrasting 
opinions 29, it seems to be established that the frequency of certain atopic disorders, 
especially asthma and allergic rhinitis, are increasing in industrialized countries 30,31, 
though, at the same time, it has not been shown that the frequency of other allergic food 
disorders is also increasing 19. 
1 0.  Oral ingestion of dietary proteins normally induces a condition of clinical tolerance. 
Without this fundamental phenomenon all feeding would quickly become impossible. 
This  "non-response"  when  a  food  antigen  is  repeatedly  administered  must  be 
distinguished from an active immunization process, in which cellular reactions take place 
and specific antibodies are produced in the presence of antigens and which, in a way, is 
the "normal" response of the organism to any antigenic attack. The characteristics of this 
tolerance acquisition process have been primarily studied in  mice 32,33. The type of 
reaction is related to the time of first antigen encounter. The early administration of 
ovalbumin to young mice induced sensitization, which was not observed when the same 
quantity of ovalbumin was given later. However, the chronic exposure to antigens after 
initial immunization modulates the immune response. Repeated doses seem to be more 
effective than a single ingestion for suppressing the hypersensitivity reaction. Repeated 
antigen feeds given to  sensitized animals can induce a "secondary tolerance" 33. Of 
course, it is difficult to extrapolate from baby mice to infants due to the differences in 
their digestive and immune-related developments. Nevertheless, it is conceivable that the 
digestive and immunological immaturity of newborns, as  in  baby mice, favors  the 
stimulation ofT-helper cells, so preventing the induction of tolerance by T-suppressor 
cells 33,34. Within the framework of this hypothesis, it might be beneficial not to feed 
very young infants the highly antigenic proteins (e.g. cows' milk proteins) 35. 
11.  Generally speaking, it is  accepted that during the first weeks of life, infants are at a 
greater risk of developing food allergy and the early exposure to cows' milk increases 
this risk, not only with regard to allergic reactions to cows' milk proteins but also the 
development of allergy to  other foods  36.  In a prospective study, it was  shown that 
almost all of the infants diagnosed as having an allergy to cows' milk in the first year had 
received a cows' milk formula before the first month of life, and more than half before 
the age of one week 37. Allergy to cows' milk proteins is observed rarely in infants who 
have been exclusively breast-fed during more than  the first three months of life.  A 
retrospective study of infants who developed an  allergy to cows' milk revealed that 
although they were breast-fed up  to  the first three months, they had in  fact received a 4  Reports of the Scientific Committee for  Food:  28th series 
quantity of cows' milk equivalent to 0.4 - 3 g of  ~-lactoglobulin during the first days 
after birth 25. However this information is contrasted by results of another randomized 
prospective study, in which the introduction of cows'milk proteins to infants during the 
first days after birth followed by breast-feeding, significantly reduced the incidence of 
allergic diseases at 18 months, compared with those not given cows' milk during the first 
days after birth. However, this difference was only observed when families at high risk, 
with two first degree relatives with atopy 38 were considered. The latter results are even 
more surprising considering that, in this connection, it is undoubtedly more dangerous to 
give cows' milk to newborns occasionally than regularly 25. 
12.  The theory that prolonged breast-feeding protects infants from the risk of subsequently 
developing asthma, eczema or other atopic diseases has long been controversial 18,39,40. 
Ever since a constantly cited study was published in 1936 41  which showed that, in a 
population of 20,000 infants, breast-feeding reduced the incidence of eczema by 7 times 
compared with artificial feeding, it has never been convincingly demonstrated that breast-
feeding has a protective effect against atopy in a normal non-selected infant population. 
On the other hand, results from prevention studies in infants at risk (family history of 
allergy and/or elevated cord blood IgE level) are contradictory, supporting or rejecting 
the assertion that breast-feeding and a delayed dietary diversification reduce the risk of 
food allergy 40. Some studies have even suggested an increase in the incidence of atopic 
diseases in infants exclusively breast-fed 18. 
13.  However, most of these are not randomized studies, thus creating biases especially with 
regard to recruitment of families. Moreover, they were not well controlled for a series of 
confounding factors, especially the age at which other foods besides milk are introduced, 
exposure to tobacco, air pollution, presence of pet animals (dogs, cats, etc.) and other 
environment-related variables 40. In reality, mothers that breast-feed their infants over a 
longer period generally diversify the diet of their infants  more progressively, less 
frequently request others to look after their infants and on the average smoke less than 
those mothers artificially feeding their infants. All of  these factors may reduce the risk of 
sensitization 40.42. Usually, these studies also have other weaknesses, especially the 
collection of a posteriori data, the absence of immunological investigations (e.g. the 
determination of specific IgE), inaccuracy regarding the duration of breast-feeding, the 
small sample size and the high number of dropouts 18,40.43. Nevertheless, if the major 
problem of these studies is the absence of  random assignment to one group or another-
breast-feeding or artificial  feeding - it  must be recognized that,  considering the 
advantages of breast-feeding, random sampling can pose ethical problems and may only 
be justifiable today in premature infants. In their case, an  increased risk of allergic 
reactions can be balanced against the demonstrated advantages of using low birth weight 
infant formulae 44. 
14.  Since the decision whether to breast-feed an infant or not must be left up to the mother, it 
is essential to ensure that the groups  are as  comparable as  possible regarding the 
identified confounding variables such as  family history of allergy and the infants' IgE 
level at birth 45. In studies where these precautions have been taken, exclusive breast-
feeding during the first 4 - 6 months after birth and delayed introduction of other food 
· significantly reduced the incidence of atopic diseases, especially eczema, and of the 
gastro-intestinal symptoms attributed to cows' milk up to the age of 12 to 36 months in 
infants at risk 26,44,45-47. 
15.  The protective effect of breast-feeding against eczema may be even more powerful if 
mothers exclude substances considered "allergenic" from  their diet, especially milk 
products, eggs, peanuts and soya. In families at risk, a randomized trial revealed that at 
the age of 18 months, eczema was two times less frequent and less severe in breast-fed 
babies whose mothers followed an exclusion diet than in those whose mothers did not Infant formulae claimed to  be  "hypoallergenic" or "hypoantigenic": 9-12-1991  5 
modify their diet during the nursing period 45. In another randomized study, the strict 
exclusion of milk, eggs and peanuts from  the mother's diet during the last three months 
of pregnancy and during breast-feeding, the use of a casein hydrolysate to supplement 
breast-feeding or to replace it, if necessary, for up to 6 months of age and the exclusion 
of a number of common food products up to the age of 2 years, helped to significantly 
reduce the incidence of food allergic diseases such as atopic dermatitis, urticaria and 
gastro-intestinal disorders. On the other hand, the prevalence of allergic rhinitis and 
asthma was not modified by this dietetic manipulation 48. However, no such favourable 
results were observed in other studies 49. 
16.  The effects of excluding food antigens from the mother's diet could be explained by the 
reduced passage of dietary substances into breast milk, such as  ~-lactoglobulin, bovine 
IgG, ovalbumin and wheat gliadin  25,50-54.  Various  allergic  disorders,  including 
anaphylactic  shock,  have  been  observed in  breast-fed infants  where  the  mother 
consumed one of these antigens 55. A correlation has been established between infantile 
colics and the consumption of cows' milk proteins by  mothers 56.  However, many 
breast-fed  infants  suffering  from  eczema  do  not  respond  to  maternal  dietary 
manipulations 57 and a "hypoallergenic" diet for pregnant or breast-feeding females is not 
without risks if  it is not accompanied by dietetic advice and appropriate monitoring 58. 
1 7.  Infant formulae based on soya proteins are suitable alternatives for cows' milk formulae 
in infants suffering from lactose intolerance or from galactosaemia. These formulae are 
also sometimes chosen by consumers who, for various reasons, do not wish to give their 
children products based on animal proteins 2. On the other hand, they are often used in 
cases where there is  suspicion or evidence of an  allergy to cows' milk protein and for 
newborns and infants of families at risk, especially in the United States of America, 
where they represent almost 25 %of the infant-formula market 2,59,60. However, there 
are very well documented reports of severe gastro-intestinal reactions in the form  of 
vomiting, diarrhoea,  weight loss,  villous  atrophy  and even characteristic  allergic 
symptoms as  a result of feeding soya proteins. Moreover, intolerance associated with 
milk or soya proteins, or successive intolerance to these proteins, has been reported, 
especially  when  soya  formulae  have  been  prescribed  for  patients  with  acute 
gastroenteritis 2,60,61. In some studies, almost one third of the infants allergic to cows' 
milk also reacted to soya 19,62,63 and, irrespective of the antigenic properties of soya, 
soya formulae  are  not considered any  less  allergenic  than  milk formulae  64.  The 
American Academy of Pediatrics has actually recommended that soya formulae should 
not be used to  treat clinical allergic reactions to cows' milk proteins and/or to  soya 
proteins 59  and, in line with the recommendations of ESPGAN 65,  the  Committee 
believes that less antigenic formulae (e.g. protein hydrolysates) should therefore be used 
in preference to soya formulae for infants  who are  allergic or who show signs of 
intolerance to dietary proteins 2. 
18.  The possibility of preventing symptoms of allergy  in  families  at risk  and in  the 
population at large through the use of soya formulae has also been called into question. 
Even extremely  well  controlled  studies  have  not  revealed  any  difference  in  the 
development of an allergy that could be related to whether infants were given cows' milk 
or soya formulae 45,66-69, while a protective effect of breast-feeding 45,67-69 or casein 
hydrolysate 45  has been confirmed in all of the studies except for one 66. Therefore, no 
reference should be made to the possible protective role of soya formulae with regard to 
allergy, which the Committee has already emphasized in a previous report 2.  Moreover, 
it must be noted that it is more difficult to exclude soya products than milk, from the diet 
of infants and young children because of the fact that soya is often added to products 
which are not assumed to contain it such as bread, sausages, etc. 
1 9.  The therapeutic efficacy of semi-elemental diets for treating proven enteropathy cases 
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products or other dietary proteins has already been proven 35,59. Most of the studies 
were carried out with high degree casein hydrolysates (Nutramigen® and Pregestimil®, 
Mead Johnson) 7-9,48,70, with peptide sizes not above 1200 daltons molecular weight 
and which nonnally do not sensitize guinea pigs or induce anaphylactic reactions in them 
71,72 even if it has been shown that these hydrolysates sometimes contain peptides which 
are large enough to be immunogenic in animals 73,74 and provoke allergic reactions in 
infants hypersensitive to dietary proteins 55,74,75,76. The good tolerance and efficacy of a 
lactoserum hydrolysate (Alfare®, Nestle) have also been supported by a number of  other 
publications 5,6,9,10 and anaphylactic reactions to this hydrolysate have only been rarely 
reported 6.77. The published works on other high degree hydrolysed  yroducts based on 
casein (Alimentum®, Ross) 78-80, lactoserum proteins (Pepti Junior®, Nutricia) 81  or a 
mixture of soya proteins and beef collagen (Pregomin®, Milupa) 10, recently introduced 
onto the market, only involve a few cases and have often only been published in the form 
of abstracts, even if some of these products are used routinely with success to treat 
infants allergic to cows' milk. 
2 0.  There is  no randomized study which has addressed the preventive effects of a high 
degree hydrolysate with regard to atopy. The only recent study is one, already cited, in 
which Nutramigen® was used alone or as supplement to maternal feeding up to the age 
of 6 months, but the associated prolonged exclusion of cows' milk and of other highly 
antigenic products makes it difficult to determine which dietetic measure (i.e. single or 
combination), is responsible for the almost 40% reduction in the prevalence of atopy at 
the age of 12 months 48. 
21.  A number of in vivo and in vitro tests have been or are being carried out by companies 
(Milupa in Belgium, France and Germany; Nutricia in the Netherlands; Nutripharm in 
France) that market infant formulae presented as "hypoallergenic" or "hypoantigenic" 
based on high degree hydrolysed milk, soya or beef collagen proteins, alone or as 
mixtures, like products traditionally used to treat cases of enteropathy with sensitization 
to dietary proteins. Up to now, no study putting forward favourable or unfavourable 
effects of  these fonnulae on the prophylaxis of atopic diseases in infants at risk has been 
published in an international, peer reviewed journal. 
2 2.  On the other hand, there is a series of studies on the effects of a lactoserum protein 
trypsin hydrolysate with a lower degree than that of other hypoallergenic formulae but 
whose allergenicity is reduced by a complementary heat treatment 82. All of the studies 
carried out with this product, sold in several EEC Member States under various Nestle 
brand names  and more recently in  the  United States  and Canada (Good Start®, 
Carnation) involved groups at risk. Hereafter in this report, this product is referred to as 
HA fonnula, for "hypoallergenic" formula. 
2 3.  It has been first shown that the early administration of this HA formula during the first 5 
days after birth in high risk infants did not lead to  any  abnormal reactions when 
reintroduced after 4 to 6 months of exclusive breast-feeding 11, while the inadvertent 
exposure to cows' milk under the same conditions induces sensitization in approximately 
one third of the infants 25.  Randomized and non-randomized preliminary studies have 
shown that there are practically no atopic symptoms at 4 months of age 12 or that atopy is 
3 times lower 83 in infants fed a HA formula compared to those receiving classical infant 
formulae. In the DUsseldorf study (FRG), practically no difference was found at the age 
of 4 months between breast-fed infants whose mothers followed an exclusion diet and 
those  fed  since  birth  with  a  HA  formula  83.  The  retrospective  analysis  (data 
questionnaires) of several  German  studies revealed that  the incidence of allergic 
symptoms at the age of 11  months in exclusively breast-fed infants was similar to that of 
infants exclusively fed with this HA formula during the first 5 days of life 84. This was 
confirmed by  a non-randomized study carried out in  Italy involving more than  300 Infant formulae claimed to  be  "hypoallergenic" or "hypoantigenic": 9-12-1991  7 
children. Here, it was reported that infants fed from birth with aHA formula, for whom 
the diversification of the diet had been delayed to the age of 6 months and who received a 
hypoallergenic diet up to the age of one year, had an cumulative incidence of allergy at 
the age of 1 and 2 years that was even lower than that of the breast-fed infant group, 
which in turn was 3 to 4 times lower than that of infants fed with cows' milk or soya 
formulae 47. In the non-randomized DUsseldorf study, at the age of 6 months, infants fed 
with aHA formula also had an incidence of atopic symptoms which was about twice 
lower than  that of breast-fed infants, partially confirming the results obtained in  a 
reduced number of infants 85. In this study, 32% of the infants fed cows' milk formulae 
since birth developed atopic symptoms compared with 6.8  % in the HA-formula-fed 
group 86. 
2 4.  Two randomized, double-blind prospective studies show the protective effects of HA 
formulae against atopy in infants at risk. In the Canadian study, 72 infants were recruited 
into each of the following groups: HA formula, conventional cows' milk formula, soya 
formula or exclusive breast-feeding during more than 4 months. While, in  the  HA 
formula group, only 5 infants (i.e. 7.4 %) developed atopic symptoms during the first 6 
months of life, 24 (35.8 %) and 25 (36.7 %) respectively of the infants fed cows' milk 
or soya developed such symptoms, especially eczema; the severity of the eczema was 
however not affected in the group fed with aHA formula and there was no significant 
difference in the severity of the other clinical symptoms in the 4 groups studied 87. In the 
first group the favourable effect of the HA formula has been confirmed at the ages of 1 
year and 18 months, the incidence of eczema and other allergy symptoms being 50 % 
lower than in the groups fed cows' milk or soya; no difference was observed between 
breast-fed infants and those fed the HA formula 88. In the Brussels randomized study, 
75 infants received one or two coded formulae, either a HA formula or a conventionally 
adapted formula during 6 months. The incidence of allergic symptoms was significantly 
reduced (p < OJXH) during this period if a hydrolysate was administered continuously 
(2/32 or 6.3 %) compared with the incidence in the group fed the adapted formula (14/35 
or 40 %).  At the  age of 1 year, 7/32 (21.8  %)  of the infants fed  the  hydrolysate 
developed atopic symptoms against 17/35 (48.6 %) in the group conventionally fed 89. 
2 5.  As has already been mentioned, acute anaphylactic reactions have been reported in highly 
sensitized subjects given high degree casein hydrolysates 55,74-76 or lactoserum proteins 
6,77  for therapeutic purposes. Similar reactions have also  been described with  HA 
formulae. In all of these cases, HA formulae were used for infants suffering from acute 
allergy to milk and/or to soya but who tolerated high degree casein or lactoserum protein 
hydrolysates  10,90-92.  This  suggests  that HA formulae  might induce anaphylactic 
reactions  more  often  than  high  degree  hydrolysates  in  infants  suffering  from 
hypersensitivity to dietary proteins 19. It should be emphasized though that, according to 
manufacturers 82, this type of hydrolysates is not meant to be used in the treatment of 
these infants and that, to our knowledge, no acute accident has been reported when HA 
formulae were used as first line treatment. 
2 6.  "Hypoallergenic" infant formulae, whether high degree hydrolysates or HA formulae, 
have been used in Europe for many years. Hundreds of thousands of infants have been 
given  them  for  several  months  and  no  unfavourable  effects  on their growth  and 
development have been observed. Clinical files, prepared within the framework of an 
application for authorization to commercialize them in those EEC Member States where 
these products are sold, show that the weight and height, and head circumference of 
infants fed "hypoallergenic" formulae are comparable with those of breast-fed infants or 
those fed artificially with conventional formulae 13,93,94. 
2 7.  Informations  provided  by  IDACE  and  manufacturers  indicate  that  the  apparent 
digestibility, protein efficiency ratio (PER) and the net protein utilization (NPU) of 8  Reports of the Scientific Committee for Food: 28th series 
different "hypoallergenic" or "hypoantigenic" formulae sold today are on a par with or 
higher than  those of casein. The heat treatments  used - pasteurization, ultra-high 
temperature treatment (UHT) - do not differ radically from those applied to standard 
infant milks, and lysin blockage is not greater than 15 %in HA formulae in which the 
antigenicity of lactoserum protein hydrolysate is  reduced by means of ultra-high 
temperature treatment, known to increase the production of  Maillard reaction products 95. 
On the other hand, whenever lysinoalanine, which can reduce the bioavailability of zinc, 
has been searched for 82, no notable quantity has ever been found in HA formulae. Its 
control however is not related to the production techniques used but related to the starting 
material since lysinoalanine is formed mainly from phosphoserine, present in casein but 
not in lactoserum (whey) proteins, and the production ofHA formulae does not facilitate 
its formation. 
2 8.  There is  still very little information in the literature on the nutritional efficacy and 
metabolic tolerance of "hypoallergenic" formulae in general. All data published are 
concerning HA formulae.  No difference has been found between breast-fed infants, 
infants fed with adapted formulae and those fed with HA formulae, with regard to total 
plasma proteins, prealbumin, retinol binding protein (RBP), transferrin, creatinine, 
calcium, phosphorus and IgG 94. The total plasma amino-acid concentration was found 
to be similar in the three groups, at the age of 5 - 6 days and at the age of one month. The 
distribution of essential and non-essential amino-acids differs only slightly from one 
group to another, for an approximate 2-fold increase in the concentration of threonine in 
infants receiving lactoserum protein trypsin hydrolysate 93,94,96. With the exception of 
threonine, the plasma amino-acid profile of  HA formulae is therefore very close to that of 
breast-fed infants. Considering the immaturity of threonine metabolic pathways at birth 
96, it  should be investigated whether ~his increase in plasma levels is found at a later age. 
Be that as it may, threonine seems to be one of the less toxic essential amino-acids in rats 
and no toxic effect of  elevated threonine levels in plasma has been observed in infants 96. 
2 9.  Experimental studies in 14 days old unweaned rats, which are an appropriate model for 
studying the absorption of  calcium and trace elements in infants, have revealed that zinc, 
copper, manganese and calcium bioavailability values for HA formulae are similar to the 
values obtained with breast milk and much higher than those found for soya formulae 97, 
in which a low bioavailability can be attributed to the elevated phytate content in soya 98-
100. No difference was found between aHA formula and a casein-based high degree 
protein hydrolysate 97, although the zinc bioavailability was lower with non-adapted 
formulae (ratio lactalbumin/casein 20:80) than with formulae enriched for lactoserum 
proteins  (60:40),  the  high degree of hydrolysis  suppressing the inhibitory effect 
connected with the chelation of zinc with casein itself and with the high-molecular weight 
phosphopeptides formed during its digestion 98-100. On the other hand, the binding of 
calcium with phosphopeptide derivatives of  ~-casein would favour its bioavailability by 
keeping it in solution, as proven by the slightly higher calcium retention with a non-
adapted formula in rhesus monkeys aged 7-8  months. In this model, no significant 
difference was observed between a HA formula and a formula with a high lactoserum 
protein content. The worst results were obtained with the soya formula and the best 
results with breast milk. The absolute quantities of calcium absorbed are nevertheless 
identical irrespective of the formula tested, including breast milk, which suggests that the 
present level of calcium and phosphorus supplements in standard or hydrolysed infant 
formulae is adequate for a normal skeletal mineralization 101. 
3 0.  Nothing indicates that the replacement of intact proteins by a hydrolysate or a mixture of 
amino-acids in rats modifies trophic or morphological parameters, the mucosa protein 
content or the enzymatic activity of the brush border 102-104. The surface unit absorption 
of amino-acids and small peptides was reduced without knowing whether this means a 
modification of the resistance of the unstirred aqueous layers or an  alteration in  the Infant formulae claimed to  be "hypoallergenic" or "hypoantigenic": 9-12-1991  9 
transport system of amino-acids and peptides  104. In any case, it is likely that these 
findings are of low physiological significance. Observations made in piglets concerning 
organ development, digestive enzyme activity and amino-acid digestibility have not 
revealed any major differences between animals fed with cows' milk, a formula based on 
hydrolysed cows' milk proteins and isolated soya proteins. Thus, it is unlikely that the 
replacement of intact proteins by hydrolysed proteins in infant formulae might cause 
major digestive disorders 105. 
31.  The "hypoallergenic" or "hypoantigenic" character of a formula can only be demonstrated 
by appropriate clinical tests. These tests must be preceded by a complete set of pre-
clinical tests combining physico-chemical and immuno-chemical methods, in order to: 
1)  characterize the molecular properties of the hydrolysate to the extent that its residual 
antigenicity can be derived from these; 
2)  assess the actual reduction of antigenicity compared with that of the proteins used, by 
in vitro as well as by in vivo tests 17,82,106. 
3 2.  In general, the narrower the molecular weight distribution of a protein hydrolysate, the 
greater seems the probability that it will have a highly reduced residual antigenicity and 
thus, be potentially hypoallergenic 17. However, sequences of 4 amino-acids have been 
recognized as immunogenic 19 and in practice, it is not possible to set an upper limit for 
the size of residual pep tides, below which hypoallergenicity could be guaranteed, even if 
polypeptides with molecular weights lower than 5000 daltons are less immunogenic and 
oligopeptides are generally not 107.  Moreover, the techniques used do not permit to 
precisely define these molecular weights. The size of peptides obtained varies according 
to experimental conditions, so that a comparison of the hydrolysates among themselves 
is only possible if the analyses are carried out simultaneously under identical conditions 
17. 
3 3.  Not all  milk proteins have the same sensitivity to endopeptidases usually used to 
manufacture hydrolysates, i.e. trypsin and pancreatin. Alpha (a) and beta (f3)  caseins,~­
lactoglobulin (LG) and a-lactalbumin (LA) are very sensitive to trypsin. A high degree 
hydrolysis of these proteins practically abolishes their capacity to sensitize (orally) or to 
provoke a reaction (intravenously) in guinea pigs sensitized to the starting proteins under 
discussion. On the other hand, immunoglobulins are more resistant and serum-albumin 
(BSA) is only slightly attacked, but they can be very rapidly denatured at ultra-high 
temperatures 95,97. 
3 4.  The sensitivity of proteins to heat varies according to the structure of the proteins. 
Lactoserum proteins, especially ~-LG, are more sensitive than caseins. Nevertheless, 
even for lactoserum proteins, the  temperatures to be  reached and the  heating time 
required to  significantly reduce  antigenicity can, owing to the Maillard reaction, 
unacceptably alter the nutritional value of products 108,109. On the other hand, epitopes 
can appear which are not present in natural proteins 82. Therefore, heat treatment alone 
cannot be used to produce good quality hypoallergenic formulae but it can be used 
together with selective hydrolysis to give more acceptable and tasteful products than high 
degree hydrolysates 82,95,107. Finally, neither the degree of hydrolysis nor the extent of 
heat treatment alone should be used as  a basis for defining the hypoantigenicity of a 
formula. Informations on the processes used should be systematically communicated to 
the responsible controlling authority, if necessary confidentially. 
3 5.  Several conditions should be fulfilled to  ensure the hypoallergenicity of hydrolysed 
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1)  that the immunoreactive protein concentration is less than 1/100 of the protein content 
nonnally present in the starting materials used,  and 
2)  that, using appropriate animal models, the oral administration of the fonnula does not 
induce sensitization (including anaphylactic shock or the development of antibodies 
detectable by passive cutaneous anaphylaxis tests) to major milk proteins, to other 
proteins present in the starting materials used or to residual peptides 14,106,110. 
The quasi-absence of native proteins  can be  assessed by  several techniques, e.g. 
electrophoresis on polyacrylamide gel (SDS-PAGE), immune-precipitation reactions on 
agarose gel (immuno-diffusion, immuno-rocket electrophoresis) and ELISA or radio-
immunological (RIA) techniques, the latter being both able to detect quantities of  (3-LG of 
the order of 10 ng/ml, i.e.  100 times lower than in  vivo methods  106. The decisive 
element in all the techniques used to detennine an interaction between a hydrolysate and a 
preformed antibody  (ELISA,  RIA, etc.) resides  nevertheless  in  the quality of the 
antiserum, and even if today it is the manufacturers' responsibility to rigorously define 
the properties of the antiserums used for their controls, it is recommended that reference 
standards be developed which can be used to compare products with one another and to 
establish indisputable limits 17. 
3 6.  Although tests of provoked passive or active anaphylaxis in animals and very sensitive 
measurements of the residual antigenicity of fonnulae must be carried out before any 
tests are perfonned involving human subjects, these techniques cannot be used for batch 
controls. Therefore, manufacturers should be recommended to carry out a number of 
tests on each batch, in particular those used to check the absence of significant quantities 
of high molecular weight polypeptides (e.g. on polyacrylamide gel) and the absence of 
immuno-diffusion precipitation  17,82 or even more sensitive and faster methods still 
being developed. In addition, it should be remembered that most of the immunological 
tests cited above only study anaphylactic responses, and that the study of cellular 
immunity may reveal cross reactions which differ from those detected by antibodies 111. 
Finally,  the  Committee  believes  that  in  vivo  and in  vitro  analyses  of residual 
immunogenicity must also involve the final product (ready for use) and not only one or 
two of  the major protein constituents of the product. 
3 7 .  Considering the incidence of food allergy in the population at large and the reduction in 
the frequency of these symptoms expected from an antigen reduced diet, it is virtually 
impossible to show that a "hypoallergenic" or "hypoantigenic" formula has preventive 
effects in a non-selected population. Nevertheless, the conditions under which clinical 
tests must be carried out cannot be dissociated from the indications proposed by the 
manufacturers and from the properties claimed for each type of  formula. 
3 8.  In line with the recommendations made by the Subcommittee on Nutrition and Allergic 
Diseases of the American Academy of Pediatrics, the Committee believes that the names 
"hypoallergenic" or "hypoantigenic" or any equivalent names  (e.g.  "with reduced 
antigenic activity") can only be used if the respective infant formula is well tolerated by 
infants with hypersensitivity to dietary proteins and whose hypersensitivity to milk 
proteins or other proteins entering the composition of the hydrolysate has been conftnned 
within two months before the test 17.  However, the Committee does  not believe it 
justified from  an  ethical  standpoint  to  use  a  double-blind placebo  test  for  this 
demonstration, as recommended by the ad hoc Subcommittee mentioned above 17, but 
thinks that an  open test is  more appropriate in  this case, provided that it involves a 
sufficient number of subjects, considering the  fact that acute reactions are always 
possible in highly sensitized subjects, irrespective of the properties of the products and 
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3 9.  In compliance with the provisions of article 6,  paragraph 4 of Council Directive No 
89/398/EEC, the labelling of these formulae and their presentation must not contain 
claims  for  any  preventive  or  therapeutic  properties.  The  claim  the  Committee 
recommends to be added to Annex IV of the Commission Directive of 14 May 1991 on 
infant formulae and follow-up formulae should only be authorized for formulae fulfilling 
the criteria stated in  the annex of the present document. In addition to  mandatory 
information and to the claim mentioned above, the labelling could also include usual 
contra-indications, especially for infants with hypersensitivity to proteins contained in the 
starting  material  of the  product,  and  possible  contra-indications  regarding  the 
combination with other foods (milk products, cereals, baby food in jars, etc. ) 110. 
4 0.  In compliance with the provisions of article 6 paragraph 2 of the above mentioned 
directive, the technical files  and all documents intended for medical experts could 
nevertheless mention the preventive properties of these products, provided that these 
have been properly established, be it to prevent transitorily or possibly permanently some 
atopic symptoms (eczema, asthma, spasmodic rhinitis, etc.) or more simply to prevent 
digestive symptoms resulting from an allergy to cows' milk proteins 110. In this regard, 
the tests must have been carried out on infants at risk fed during at least 4-6 months with 
the respective formula, using a double-blind, randomized protocol including a standard 
infant formula 17. 
4 1.  Except for the modifications introduced during the formulation of the product and its 
production in order to guarantee its hypoantigenicity, infant formulae claimed to have 
"hypoallergenic" or "hypoantigenic" properties should satisfy all of the criteria of 
essential composition listed in Annex I of the directive on infant formulae and follow-up 
formulae.  Their nutritional efficacy should also be demonstrated in all cases by  a 
longitudinal study on weight and height development over at least 3 months, involving at 
least 20 babies born at full term and aged less than 1 month at the beginning of  the study. 
Finally, the Committee believes that besides all the indispensable information on the 
properties of the hydrolysate and the procedures used (enzymes, molecular weight 
distribution, percentage of blocked lysin, PER, NPU, etc.), the information should be 
complemented, if necessary, by data on the plasma levels of albumin and short half-life 
proteins (prealbumin, RBP, transferrin), and on the plasma amino-acid profile. 
Conclusions  and  recommendations 
4 2.  Exclusive breast-feeding in infants at risk during 4-6 months and a delayed introduction 
of foods  other than  milk  significantly reduces  the  incidence of atopic  symptoms, 
especially eczema, and of gastro-intestinal symptoms attributed to cows' milk, at least up 
to the age of 12 to 36 months. 
4 3.  Soya formulae cannot be considered less allergenic than milk formulae. In the absence of 
maternal milk, less antigenic formulae (e.g. protein hydrolysates) should be used for 
infants at risk, allergic infants and those showing clinical signs of intolerance to dietary 
proteins. 
4 4.  The therapeutic efficacy of high degree hydrolysates in cases of enteropathy caused by 
cows' milk proteins, and in infants showing anaphylactic reactions to milk products or to 
other dietary proteins has been well established. However, this does not completely 
exclude the possibility of anaphylactic reactions in highly sensitized infants receiving 
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4 5.  The incidence of intolerance to dietary proteins is also significantly reduced in infants 
receiving a low degree lactoserum (whey) protein hydrolysate when its allergenicity has 
been reduced by  an additional heat treatment. These HA formulae too can induce 
anaphylactic reactions in hypersensitive infants, perhaps more often than high degree 
hydrolysates, but, according to the manufacturers, they are not intended for therapeutic 
use in these infants and no adverse reactions have been reported when these formulae 
were used in the first instance or for a prophylactic indication. 
4 6.  The protective effect of HA formulae with regard to atopy has been demonstrated by 
prospective double-blind studies with infants at risk. The incidence of eczema and other 
allergic symptoms is similar as in breast-fed infants and two times less than in infants fed 
with cows' milk or soya infant formulae; this reduction continues at least up to the age of 
12 to  18  months. Comparable results have been obtained with a high degree casein 
hydrolysate. This randomized study where the hydrolysate was  used alone or as a 
supplement to breast milk up to the age of 6 months, a strict exclusion of various 
antigens from the mother's diet during the end of  pregnancy and lactation periods and a 
delayed introduction of a number of common foods into the diet of the infants up to the 
age of  2 years is difficult to interpret because of the additional dietary modifications. 
4 7.  Infant formulae claimed to be  "hypoallergenic" or "hypoantigenic" or those "with 
reduced antigen or allergen content" have been used in several Member States for years 
and no undesirable effects on the growth or development of infants have been observed. 
Their indications, which are not the purpose of this report, remain to be discussed. Some 
people are of  the opinion that they must be reserved for infants at risk and/or for infants 
with clinical intolerance symptoms, and others believe that they are contra-indicated for 
infants suffering from acute reactions to their constituting proteins and that their main 
indication is prophylactic. Considering the information at its disposal, the Committee 
believes that it is premature to make any recommendation on this  matter, as  the 
indications of the products undoubtedly differ, depending on the raw materials and the 
processes used. The Committee also believes that, no matter what results are obtained 
with these products, the provisions of the WHO Code on the marketing of breast milk 
substitutes must be strictly respected,  and that public authorities must ensure that 
commercial practices and the information provided to medical and health professionals do 
not in any way discourage mothers from breast-feeding their infants. 
4 8.  In any case, the Committee considers that manufacturers should guarantee that such 
products satisfy the following criteria to be able to claim an "hypoallergenic" or "with 
reduced allergen content" or "hypoantigenic" or "with reduced antigen content" status: 
- the proteins must have been treated in such a way that the immunoreactive protein 
amount, measured with the appropriate methods (SDS-PAGE, immuno-diffusion, 
ELISA, RIA, or any other method with equivalent sensitivity), is lower than 1 %of 
that of nitrogen-containing substances in the formula; 
the criteria relating to protein given in the Annex of this report must be fulfilled. In 
addition, these formulae must satisfy all other relevant criteria regarding the essential 
composition of infant formulae as stipulated in Commission Directive 91/321/EEC on 
infant fonnulae and follow-on fonnulae; 
proof of the absence of any sensitizing character should be supported, before any 
clinical test, by  a  series of tests on laboratory animals  under conditions where 
provocation tests show anaphylactic reactions in animals having received orally (or via 
other appropriate routes) the intact proteins from which the formula is derived; 
the clinical tests must have proven their tolerance in  more than 90 % (confidence 
interval 95 %) of the infants suffering from a hypersensitivity to proteins from which 
the hydrolysate is made, unless the labelling and presentation of these formulae clearly 
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4 9.  Their nutritional efficacy must have been demonstrated by means of  clinical tests carried 
out according to recognized adequate protocols. 
50.  The labelling and presentation of these formulae should not mention any preventive or 
therapeutic properties. The technical files and documents intended for medical and health 
professionals can however mention their preventive properties, provided that these have 
been established by randomized, double-blind studies using the respective formula. 
5 1.  The manufacturers must keep at the disposal of the responsible authority all relevant 
information concerning the properties of the hydrolysate and the processes used. 14  Reports of the Scientific Committee for Food:  28th series 
Annex 
Protein  requirements  for  formulae  manufactured 
from  hydrolysed  proteins 
Minimum 
0.56 g/100 kJ 
(2.25 g/100 kcal) 
Maximum 
0.7 g/100 kJ 
(3 g/100 kcal) 
•  The chemical index shall be equal to at least 80% of that of the reference protein (breast 
milk, as defined in Annex VI of Commission Directive 91/321/EEC). 
•  For an equal energy value the formula must contain an available quantity of  each essential 
and semi-essential amino-acid at least equal to that contained in the reference protein 
(breast milk, as defined in Annex V of Commission Directive 91/321/EEC). 
•  The protein efficiency coefficient (PER) and net protein utilization (NPU) must be at least 
equal to those of casein. 
•  The taurine content shall be equal to at least 10 ~oles/100  kJ (42 J.lmoles/100 kcal) and 
the L-carnitine content shall be equal to at least 1.8 J.lmoles/100 kJ (7.5  J.lmoles/100 
kcal). Infant formulae claimed to  be "hypoallergenic" or "hypoantigenic": 9-12-1991  15 
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Terms  of reference 
To advise on the addition of some nucleotides to the list of nutritional substances which may be 
added in the manufacture of infant formulae and follow-on formulae. 
Introduction 
1.  The Committee has adopted up to now two reports on infant formulae and follow-on 
formulae based on cows' milk proteins and soya proteins 1.2. It recently reconsidered its 
recommendations concerning the maximum level of vitamin D content of these products 
and approved a limited extension of the list of nutritional substances which may be added 
in their manufacture 3. The second addendum to the above mentioned reports concerns 
the addition to infant formulae and follow-on formulae of nucleotides normally present in 
human milk and which are semi-essential compounds, especially during the first months 
of life. 24  Reports of the Scientific Committee for Food:  28th series 
Definitions 
2.  The definitions adopted in the above mentioned reports 1,2 and in the first report of the 
Committee on the essential requirements for weaning foods 4 have been retained. 
Documents  consulted 
3.  In drafting this opinion the Committee considered relevant scientific publications and 
information provided by the Association of  Dietetic Food Industries of the EEC (IDACE) 
in particular concerning the specifications and the purity criteria of nucleotides. 
Scientific  background 
4.  Nucleotides are the basic building blocks of the nucleic acids RNA and DNA. They are 
comprised of one or more phosphate groups, of a pentose, either ribose or deoxyribose 
and a nitrogenous base. The nitrogenous bases are either purines (adenine, guanine, 
hypoxanthine or xanthine) or pyrimidines (uracil, cytosine or thymidine). Nucleotides 
are involved in other cellular functions such as in energy transfer or as modulators of 
enzyme activity 5. 
The purine and pyrimidine bases can be synthesized in the body from  amino-acid 
precursors  and can also  be re-synthesized in  the salvage pathway from  catabolic 
intermediaries. The latter is the quantitatively more significant accounting for up to 90% 
of the purine bases. Certain tissues preferentially utilize the salvage pathway eg. the 
intestinal  mucosa,  bone  marrow,  hematopoietic  cells  such  as  leukocytes  and 
erythrocytes. The de novo synthesis pathway and the salvage pathway are inversely 
related, the former being activated by the absence of nucleotides and the latter stimulated 
by their presence in the diet 6-8. 
5 .  For certain cells such as lymphocytes or intestinal epithelial cells where growth and 
turnover can be rapid, dietary purines and pyrimidines can be considered as  semi-
essential. The rat's small intestine lacks the de novo synthetic pathway and the level of 
gut RNA falls on purine and pyrimidine deficient diets 9. High density lipoproteins are 
increased in infants and experimental animals by nucleotide feeding and the elongation 
and desaturation of essential fatty acids are increased in  neonatal infants and rats by 
dietary nucleotides 10. 
Iron bioavailability is influenced by inosine monophosphate (IMP) which is derived 
from the catabolism of adenosine monophosphate (AMP) 11,12. IMP also plays a role in 
the T-cell mediated immune response 13 and nucleotides may be components of human 
milk that contribute to the enhanced immunity of the breast-fed infant 14. In rats with 
70% hepatectomy, liver regeneration is increased by intravenous administration of 
nucleotides. Intestinal recovery following diarrhoea may also be improved by dietary 
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6.  Nucleoproteins, widely present in food, are digested by proteolytic enzymes to release 
nucleic acids. Pancreatic nucleases degrade nucleic acids into a mixture of mono-, di-, 
tri-,  and polynucleotides.  Intestinal  alkaline  phosphatase converts  nucleotides  to 
nucleosides releasing free phosphate, and nucleosidases convert nucleosides to the 
pentose and to free purine and pyrimidine bases 16,17. Together, alkaline phosphatase, 
nucleotidases and nucleosidases generate a mixture of free purine and pyrimidine and 
nucleosides. It is in the latter form that they are absorbed by facilitated diffusion and by 
sodium dependent transporters 18. 
7.  Foods such as  offal, sea-foods and dried legumes are especially rich in nucleotides. 
Cows' milk is low in nucleotides especially those based on cytosine and adenosine. It 
does, however, contain a  high level of orotate.  Both goat and sheep milk contain 
considerably more (four and five times respectively) nucleotide than cows' milk and 
colostrum contains more than mature breast milk 19,20. 
8 .  Human milk is richer in nucleotides in comparison to cows' milk. Taking into account 
the total nitrogen content, nucleotides represent in human milk a higher percentage than 
in ruminant milks. As much as 30% of the total nitrogen in human milk is nonprotein 
nitrogen (about 5% in cows' milk) and soluble nucleotides contribute as much as 20% of 
the nonprotein nitrogen. As  in other species, the nucleotide content of human milk 
decreases with advancing lactation, except for IMP which increases. There is variability 
in the levels of specific nucleotides which can be attributed to the individuals per se and 
also to the methods of sample preparation and analysis.  The Committee has  thus 
considered only the values obtained with the more recent techniques using HPLC and 
enzymatic methods. 
9.  Cytidine and uridine nucleotides represent the most important fraction of the  total 
nucleotides in human milk. Total uridine derivatives reach an average up to 5.4 Jl.mOl/dl 
(range: 4.9- 7.5) and total cytidine derivatives an average 3 J.lmol/dl (range: 2.2-4.9). 
The average for adenosine derivatives is 2.9 J.lmol/dl  (range: 2.1  - 3.5) and that for 
guanosine derivatives is 0.8 J.lmol/dl (range: 0.6- 1.3) 21. AMP and CMP represent the 
majority of adenosine and cytidine nucleotides. Uridine monosphosphate (UMP) and 
guanosine monophosphate (GMP) are about 20 to 25% of total uridine and guanosine 
derivatives. 
IMP is also present in human milk and no other inosine derivatives have been found. 
Orotate is practically absent in human milk. 
1 0.  Supplementation of infant formulae with nucleotides is authorized in Japan from  1965, 
in Spain from 1983 and in the United States from  1989. Only nucleotides in the form of 
monophosphate salts  are  used for  supplementation,  the  total  amount added being 
comprised between 2 and 5 mg/1 00 kcal  in  the marketed formulae.  Considering the 
consumption  of energy of young  infants,  the  intake of nucleotides  of those  fed 
supplemented infant formulae is in  the same order as  that of breast-fed infants (11-18 
mg/day) 9. 
11.  Until now,  the Committee, like JECFA,  has  allocated an  ADI not specified for 5'-
ribonucleotides. Likewise the Committee has allocated an ADI not specified for specific 
nucleotides such as inosinic acid and its salts (E 630-633) and guanylic acid and its salts 
(E 626-629). Nevertheless studies on the effect of oral purines on serum and urinary uric 
acid of healthy hyperuricemic and gouty adult humans suggest that the purine derivatives 26  Reports of the Scientific Committee for Food: 28th series 
except those derived from  guanine, increased serum uric acid concentrations 22.  So, 
several reports suggest that the maximum safe limit of ribonucleotides daily intake in the 
diet of adults would be 2 g, i.e. 30 mg!kg body weight 22. The intake of nucleotides of 
breast-fed infants and of supplemented milk formulae is about 10 times less than the 
suggested maximum daily intake for adults. 
Conclusions 
12.  There is not any sign of clinical deficiency which may be attributable to the lack of 
nucleotides in infant formulae. However it is well established that dietary nucleotides 
play a role in a number of physiological functions, namely lipid metabolism, immune 
response,  tissue  repair and possibly  iron  absorption.  The exogenous  supply  of 
nucleotides may be important especially for those tissues with a high turnover. 
13.  Human milk has a specific nucleotide profile which differs from that of  ruminant milks. 
The total nucleotides content in human milk ranges  between 5 to  15  ~mol/dl, i.e. 
approximately 2 to 6 mg/100 kcal. Thus the Committee considers that if  infant formulae 
are supplemented with nucleotides it is advisable to supplement in the same order of 
concentrations as found in mature human milk. 
14.  There are no long term studies for infants fed nucleotide supplemented milk formulae. 
However, those products have been used in the United States, Japan and Spain for years 
and no deleterious effect has been reported. Therefore the Committee does not have any 
theoretical reason to think about negative effects of those formulae, at least within the 
range of nucleotide concentrations used until now. 
15.  A large number of  children are still fed with infant formulae after 4-6 months of  age. The 
amount of nucleotides likely to be added to either infant formulae or follow-on formulae 
would represent a very small proportion of the total intake of purine and pyridine bases 
in a diversified feeding pattern. The Committee considers that, while there would be no 
benefit to adding nucleotides to follow-on formulae, there is no reason to believe that this 
would have  negative consequences,  provided  they  are  added at  the  same levels 
recommended for infant formulae. 
16.  Although human milk contains at least 12 acid soluble nucleotides, the opinion of the 
Committee is to limit the list to the following nucleotide-5'monophosphates: CMP, 
UMP, AMP, GMP and IMP, which are hydrolysed in the intestine and absorbed as 
nucleosides. Only the sodium salts of those nucleotides, easily soluble in water, should 
be authorized. The total concentration of those nucleotides in the ready to use products 
should be in the same order of magnitude as in human milk and in any case less than 5 
mg/100 kcal. The maximum limit for each nucleotide should be: 
CMP:  2.5  mg/100 kcal 
UMP:  1.75  mg/100 kcal 
AMP:  1.5  mg/100 kcal 
GMP:  0.5  mg/100 kcal 
IMP:  1  mg/100 kcal Second Addendum: Nucleotides in  infant formulae and follow-on formulae: 9-12-1991  27 
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Terms  of reference 
To advise on foods for particular nutritional uses whose sodium content has been modified. 
1.  Dietary  sodium  in  Europe 
1. 1  The sodium which is present in the diet as eaten has three distinct origins. The first one 
is represented by the sodium naturally present in foods  and drinking water. Natural 
sodium content rarely exceeds values of 100 mg per 100 grams or 100 kcal (420 kJ) (see 
Table 2). The second source of sodium is represented by the salt (NaCl) which is added 
to foods, and as sodium salts of food additives, during various stages of their industrial 
processing and/or manufacturing. These food additive sources account for less than 10% 
of total sodium intake 22. Processed foods tend therefore to be much richer in sodium 
than natural foods (see Table 1). The third source of dietary sodium is represented by the 
salt which is added to foods by the individual consumer during the domestic stages of 
preparation of the meals and/or at the table. This salt, being under the control of the 
individual consumer, is usually referred to as "discretionary" salt. 
1. 2  Total dietary sodium intake in the European region has been estimated to range between 
3.5 and 5 g/day (9 to 12 g NaCI/day) 15. The proportion of total sodium contributed by 
discretionary salt is  not firmly established, but recent evidence suggests it may range 
between 20 and 40% of total sodium intake 16,18, although it has also been seen to drop 
down to only 2%  13,24. This confirms that the major source of dietary intake of salt is 
currently from industrially processed foods 3,8,12. The major sources of sodium are, for 
most countries, bread and other cereal and bakery products; the combined group of 
meats, fish, and eggs follows closely, and milk products come next (Tables 3 and 4). 30  Reports of the Scientific Committee for  Food:  28th series 
2.  Rationale  for  low  salt  intakes 
2. 1  Salt consumption, and sodium in particular, has been firmly linked to hypertension, both 
for its  role in its pathogenesis and, even more so, for its treatment 7,9,10,21,25,28,29. 
While there  is  a  continuing controversy  about  the  exact nature  of the  sodium-
hypertension link, a large body of scientific evidence is available to show that high salt 
intakes are a necessary but not sufficient condition for inducing essential hypertension in 
all individuals (the Salt Hypothesis) 5. On a population basis, it has been established that 
the habitual consumption of more than 6 g/day of salt is associated with an age-increase 
in blood pressure 15. As for the hypertensive patient, the evidence shows that the blood 
pressure of most hypertensive falls following the reduction of their salt intakes 2,4,14,19. 
The benefits of lowering blood pressure are further magnified by  the concurrent 
reduction of the dependence on hypotensive drugs, which may have undesirable side 
effects. 
2. 2  On the basis of the above mentioned scientific evidence authoritative bodies have 
recommended that the total amount of dietary salt be maintained at about 5-6 g/day 1,27. 
Such recommendations are addressed to the general public. However, it is recognized 
that genetically salt susceptible individuals and hypertensives will particularly benefit 
from low sodium diets, the salt content of which should range between 1 and 3 g/day. 
3.  Salt modified  products 
3. 1  Individuals who wish or need to control the sodium content of their diet could do so by 
modifying certain habits and appropriately selecting common foodstuffs. Indeed the 
addition of salt during cooking or other meal preparation and at the table could be 
reduced.  There are  foodstuffs  which naturally contain  a  low amount of sodium. 
Manufacturers, responding to expert recommendations and demand of the public, are 
marketing an ever increasing variety of common foodstuffs the sodium content of which 
is significantly less than in the past. 
3. 2  Dietetic products specially manufactured for the dietary management of certain conditions 
needing a well defined reduced Na content and clearly presented as such, comprise two 
distinct types: 
a)  sodium-modified foodstuffs to be consumed as such;  and 
b)  sodium-modified salt  substitutes  which  are  added to foodstuffs  during  their 
preparation and/or at the table. 
This report deals with these two types of products. 
4.  Overview  of standards  for  low  sodium  products 
4.1  Codex has established a standard for low sodium dietary foods and salt substitutes 6. It 
describes these foods as being intended for special dietary uses by reason of their low 
sodium content and contemplates two categories, the low  sodium and the very low Low sodium foods  and salt substitutes: 9-12-1991  31 
sodium products. For both, a three pronged definition is used, namely that the food be 
processed without adding salt, that the final sodium content be no more than half the 
amount contained in the normal-salt version, and that it does not exceed the threshold of 
120 mg (low  sodium)  and 40 mg (very  low  sodium) per 100 g  final  product as 
consumed. 
4. 2  The U.S. regulation for sodium labelling 26 distinguishes four categories based on the 
sodium content per serving: sodium free (less than 5 mg), very low sodium (up to 35 
mg), low sodium (up  to  140 mg) and sodium reduced (with a 75% reduction over 
comparable normal product). 
4. 3  The regulation in the various EC member countries is very diverse and incomplete. In 
Italy an internal normative of the Ministry of Health is concerned with salt substitutes. 
Two types of salt substitutes are permitted, namely a low-sodium and an a-sodium salt 
substitute. No regulations exist for sodium modified foods. Spain, Germany, Belgium 
and France have specific regulations regarding sodium modified dietetic foods and salt, 
the amounts of sodium  permitted and the  various  specifications varying modestly 
between countries. The UK, while not having specific regulations in this domain, has 
nevertheless clear recommendations. Most of these countries contemplate two categories 
of products, except for France and Belgium that specify the diverse sodium content for 
various food products, and the UK which considers three categories, sodium-reduced, -
low, and -free. 
5.  Rationale  for  the  recommendations 
5. 1  In making its recommendations the Committee based its rationale on the principle that 
consumption of low sodium dietetic foods, exclusively or in combination with low 
sodium common foods, should permit individuals with, or susceptible to developing 
hypertension to have a sodium intake approximately half of the amount recommended for 
the general population (i.e. 0.4- 1.2 g Na/day or 1-3 g NaCI/day). 
5.  2  In agreement with Codex the Committee considers that it is necessary to adopt as an 
essential requirement for these products, a substantial reduction in their sodium content 
with  respect  to  their common  foodstuffs  counterparts.  The  Committee  has  also 
considered that this  principle of reduction  of sodium  with  respect to  the  normal 
counterpart is without meaning if these reference foodstuffs are naturally low in sodium 
(i.e. less than 100 mg/100 g or 100 kcal or 420 kJ). A lower limit for the sodium content 
of the latter seems therefore justified as an additional criterium. 
6.  Definition  of the  categories 
6.1  The very low-sodium food definition applies to  special dietary foods  whose final 
total sodium content is less than 40 mg/100 g of the ready to consume product, and 
this final concentration is less than half the concentration present in its regular equivalent, 
whose initial sodium concentration must be higher than  100 mg sodium per 100 g or per 
100 kcal (420 kJ), whichever of these is the lowest. 32  Reports of the Scientific Committee for  Food:  28th series 
6. 2  The low-sodium food definition applies to  special dietary foods  whose final  total 
sodium content is less than 120 mg/100 g of the ready to consume product, and this 
final concentration is less than half the concentration present in its regular equivalent, 
whose initial sodium concentration must be higher than 100 mg sodium per 100 g or per 
100 kcal (420 kJ), whichever of these is the lowest. 
6.  3  Salt substitutes are divided into 3 categories corresponding respectively to products 
whose sodium content is less than 12 g/100 g of the salt mixture (sodium-reduced salt 
substitute), or less than 120 mg/100 g of the salt mixture (low-sodium salt substitute), or 
less than 10 mg/100 g of the salt mixture (sodium-free salt substitute). In sodium-free 
salt substitutes, potassium is most commonly used to replace sodium. The potassium 
content in these products should not exceed 30 g/100 g of the salt mixture in view of its 
reduced organoleptic acceptability and the risk of hyperkaliaemia in  subjects with 
impaired renal function 5,20,23. 
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Table 1:  Sodium and salt in  processed foods 
of common  use  in  Europe 
Data expressed on the basis of net edible weight {mg/100 g) and of energy content {mg/100 kcal or mg/420 kJ) 
as mg/100g  as mg/1 OOkcal or  Category* 
mg/420 kJ  Sodium density 
Sodium  NaCI  Sodium  NaCI 
Brie cheese (27.9% fat)  a  1117  2840  310  790  H 
Camembert (22.3% fat)  a  970  2467  320  820  H 
Cheddar (32.2% fat)  a  675  1717  160  420  H 
Parmesan  a  704  1790  180  450  H 
Butter (salted)  b  750  1907  100  260  :MH 
Margarine {standard)  a  101  257  10  30  L 
Comedbeef a  833  2118  550  1390  H 
Fried bacon  b  1820  4628  370  930  H 
Ham, canned  a  1200  3052  630  1600  H 
Ham, raw, smoked dried  a  1400  3560  350  900  H 
Pork pie  b  720  1831  190  490  H 
Sausage roll  b  550  1399  110  290  :MH 
Sausage {bockwurst)  a  700  1780  240  610  H 
Herring, in tomato sauce  a  526  1338  250  640  H 
Salmon,canned  a  540  1373  300  770  H 
Salmon in oil  a  4070  10350  1410  3580  H 
Sardine in oil  a  505  1284  210  540  H 
Tuna in oil  a  361  918  120  300  :MH 
Potato flakes, dried  a  160  407  50  130  MI.. 
Potato fried slices  a  450  1144  80  210  :MH 
Potato fried sticks  a  720  1831  140  360  H 
Salad cream  b  840  2136  270  690  H 
Vegetable soup  b  500  1272  1350  3440  H 
Oxo cubes  b  10300  26193  4500  11440  H 
Asparagus, canned  a  355  903  3550  9030  H 
Spinach, canned  a  170  432  1420  3600  H 
Beans french, canned  a  275  699  4580  11660  H 
Pea, canned, drained  a  211  537  750  1920  H 
Tomato, canned  a  9  23  150  380  H 
Tomato juice  a  5  13  30  80  L 
Comflourd  52  132  10  40  L 
Pop Com  e  1940  4933  430  1080  H 
Macaroni, raw  d  11  28  traces  10  L 
Macaroni, canned, cheese sauce  d  560  1424  410  1030  H 
Ravioli, canned, tomato sauce  d  490  1246  700  1780  H 
Pizza  d  540  1373  220  550  H 
White bread (average)  d  520  1322  220  560  H 
Wholemeal bread (average)  d  550  1399  260  650  H 
Rusk (cracker)  a  263  669  70  180  MI.. 
Com flakes  d  1110  2823  310  790  H 
Muesli Swiss style  d  380  966  100  270  :MH 
Rice K.rispies  d  1260  3204  340  870  H 
Weetabix  d  370  941  110  280  :MH 
Digestive biscuits plain  d  600  1526  130  320  H 
Semi sweet biscuits  d  410  1043  80  230  :MH 
Sponge cake butter  d  360  915  70  190  MI.. 
Fruit cake  d  250  636  70  180  MI.. 
Madeira cake  d  380  966  100  250  :MH 
Teacakes  d  270  687  90  230  MH Low sodium foods  and  salt substitutes: 9-12-1991  35 
Table 2:  Sodium  and salt in  natural/unprocessed foods 
of common  use  in  Europe. 
Data expressed on the basis of net edible weight (mg/100 g) arid of energy content (mg/100 kcal or /420 kJ) 
as mg/100 g  as mg/100 kcal or  Category* 
mg/420 kJ  Sodium density 
Sodium  NaCI  Sodium  NaCI 
Human Milk  a  16  41  23  57  L 
Cows' milk (3.5% fat)  a  48  122  72  182  ML 
Cream (30% fat)  a  34  86  10  30  L 
Egg (chicken)  a  144  366  86  219  MH 
Meat (meat only)  a  57  145  50  127  ML 
Herring, raw  a  117  298  53  134  ML 
Salmon, raw  a  51  130  25  60  L 
Sardine, raw  a  100  254  74  188  ML 
Tuna, fresh  a  43  109  18  45  L 
Apple  b  2  5  4  11  L 
Orange  b  3  8  9  22  L 
Potato  a  3  8  4  10  L 
Asparagus  a  4  10  29  73  L 
Beetroot c  84  214  420  1068  H 
Spinach  a  65  165  433  1102  H 
Beans, fresh  a  2  5  5  14  L 
Tomato  a  6  15  35  90  L 
Rice  b  6  15  2  4  L 
Flour, whole  b  3  8  9  22  L 
*  Sodium density categories on the basis ofNaCI mg/100 kcal: 
-L=  low  <110 mg/100 kcal 
-ML=  medium low  110-210 mg/100 kcal 
-MH=  medium high  210-310 mg/100 kcal 
-H=  high  >310 mg/100 kcal. 
a  Souci SW, Fachmann W & KrautH, (1986). Food composition and nutrition tables 1986187. 
3rd ed., Wissenschaftliche Verlagsgesellschaft mbH Stuttgart. 
b 
c 
d 
e 
Paul AA & Southgate DAT, (1978). McCance and Widdowson's The composition of  foods, 4th 
ed., London: HMSO. 
Camovale E & Miuccio F, (1990). Tabelle di composizione degli alimenti. Istituto Nazionale 
della Nutrizione. Roma. 
Holland B, Unwin ID & Buss DH, (1988). Cereals and cereal products, The  third suppl to 
McCance & Widdowson's The composition of  foods, 4th ed., London, Royal Soc. Chern. & 
MAFF. 
Watt BK, Merill AL, (1975). Composition of foods. Agricultural Handbook n°8. Agricultural 
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Table 3:  Sodium  content of total  diet 
(in  grams/day/pro  capita) 
and  percent contribution  from  specified  food  groups 
Germany 1  Finland 2  Britain 3  America 4 
(as  percent of total) 
Cereal&  34  20  40  29 
cereal products 
Egg, meat & fish  34  15  29  14**** 
Milk&milk  d  11  7**  10 
products 
Fats  1  10  16*  6 
Veg. & fruits  4  1  6***  11 
Sugar, candy,  16  43  30 
beverages & salt 
added in food prep. 
(in  grams/day/pro  capita) 
Total  2.86  4.20  2.60  6.69 
*  Included cheese, cream and ice cream 
**  Only milk 
***  Only vegetables and roots 
****  Excluded eggs 
Docum. IDACE (1988).  1 
2  Pietinen P,  (1982).  Estimating Sodium  Intake from  Food  Consumption Data. Ann. Nutr. 
Metab. 26: 90-99. 
3 
4 
Bull BN, Buss DH, (1980). Contributions of foods to  sodium intakes. Proc. Nutr. Soc. 39: 
30A. 
Shank FR,  Kang Park Y,  Harland BF,  Vanderveen JE, Forbes AL and Prosky L, (1982). 
Perspective of Food and Drug Administration on dietary sodium. JADA, 80: 29-35'. Low sodium foods and salt substitutes: 9-12-1991  37 
Table  4:  Consumption  of sodium from  specified  food  groups  in  Italy 
(mg/day/pro  capita ) 
and as  percent of their contribution to total  intake *. 
mg/d/pc  % 
Cereals & cereal products  833  28.5 
Milk & dairies  369  12.6 
Cured meats (hams, sausages, etc)  245  8.4 
Meat & fish  107  3.7 
Vegetables, fruits & pulses  98  3.3 
Eggs  33  1.1 
Beverages  20  0.7 
Ready meals  16  0.5 
Fats  16  0.5 
Processed fish  16  0.5 
Biscuits & cake  14  0.5 
Seasonings & sauces  6  0.2 
Baby foods  3  0.1 
Salt added in food preparation  1147  39.3 
Total  diet  2922  100.0 
* Cialfa F,  Unpublished data on 10.000 households. 38  Reports of the Scientific Committee for Food:  28th series 
Table 5:  Sodium  content of regular and  low  sodium 
processed  foods* 
Cereal  products 
Whole wheat bread 
Multi  grain 
Breakfast cereals 
Crackers 
Crisp  bread 
Spreads 
Butter 
Margarine 
Peanut butter 
Snack  foods 
Cashewnuts 
Peanuts 
Potato chips 
Soups 
Chicken 
Chicken noodle 
Tomato 
Mushroom 
Canned  vegetables 
Canned peas 
Canned tomatoes 
Tomato sauce 
Tomato paste 
Tomato juice 
Canned  fish 
Pink salmon 
Tuna 
* 
0 
# 
From Greenfield et al.,  11 
Labelled as lightly salted 
Not available. 
Regular 
450 
460 
190 
1000 
530 
700 
700 
500 
400 
500 
400 
380 
450 
350 
310 
290 
280 
1000 
530 
280 
410 
400 
Na  content mg/100  g 
Low salt or 
sodium reduced 
200 
200 
# 
540 
# 
340 
400 
# 
# 
240 
360 0 
200 
240 
180 
150 
# 
# 
# 
# 
# 
# 
# 
Saltfree or no 
added salt 
24 
# 
14 
# 
62 
19 
6 
18 
18 
10 
26 
100 
# 
36 
4 
15 
26 
40 
7 
110 
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